The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Clinical Readouts

Mersana Therapeutics Inc MRSN will present interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-small cell lung adenocarcinoma.

See also: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

ASCO Presentations

Friday

• Arvinas Inc ARVN: additional Phase 1 data on ARV-110 in castration-resistant prostate cancer
• Trillium Therapeutics Inc TRIL: updated Phase 1a/b data on TTI-622 in refractory lymphoma or multiple myeloma
• Cardiff Oncology Inc CRDF: Phase 1b/2 data on onvansertib, folfiri and avastin in KRAS-mutated colorectal cancer
• Iovance Biotherapeutics Inc IOVA: new interim Phase 2 data on LN-144-lifileucel in refractory metastatic melanoma
• Blueprint Medicines Corp BPMC: updated Phase 1/2 data for praksetinib in RET-altered tumors
• Allogene Therapeutics Inc ALLO: Initial Phase 1 data for ALLO-501 in non-Hodgkin lymphoma
• Deciphera Pharmaceuticals Inc DCPH: Phase 1b/2 data on rebastinib and paclitaxel in solid tumors
• GENMAB A/S/S ADR GMAB: Phase 1/2 data on epcoritamab in B-cell lymphoma
• AVEO Pharmaceuticals, Inc. AVEO: Phase 3 data for tivozanib in third-line treatment of patients with renal cell cancer
• Merck: Phase 3 data for Keytruda in colorectal cancer
• Amgen, Inc. AMGN: updated Phase 1 data for AMG 510 in solid tumors
• IMMUTEP LTD/S ADR IMMP: initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer, head and neck cancer
• Heat Biologics Inc HTBX: Phase 2 data on HS-110 and Opdivo in non-small cell lung cancer
• Autolus Therapeutics Ltd – ADR AUTL: updated Phase 2 data for AUTO3 in relapsed or refractory diffuse large B-cell lymphoma
• Oncolytics Biotech, Inc. ONCY: interim Phase 1 data for pelareorep and carfilzomib/dexamethasone in multiple myeloma; interim Phase 2 data for pelareorep with Keytruda in pancreatic cancer
• Athenex Inc ATNX: Phase 2 data on oraxol in angiosarcoma
• Harpoon Therapeutics Inc HARP: preliminary Phase 1 data on HPN424 in metastatic castration-resistant prostate cancer
• Gossamer Bio Inc GOSS: initial Phase 1/2 data on GB1275 in solid tumors
• ImmunoGen, Inc IMGN: initial Phase 1b/2 data for mirvetuximab soravtansine in ovarian cancer and relapsed endometrial cancer
• Merus NV MRUS: Phase 2 data for MCLA-128 in breast cancer
• CytomX Therapeutics Inc CTMX: Phase 1 data for CX-2029 in solid tumors/diffuse large B-cell lymphoma; initial Phase 1 data on BMS-986249 and Opdivo in solid tumors or lymphomas
• Corvus Pharmaceuticals Inc CRVS: initial Phase 1b/2 data for CPI-444 in solid tumors
• Pfizer Inc. PFE: Presentation of data on Bavencio in bladder cancer
• CELYAD SA/ADR CYAD: Phase 1 data on CYAD-101 in colorectal cancer
• Immunomedics, Inc. IMMU: Phase 2 data on sacituzumab govitecan in urothelial cancer
• Xencor Inc XNCR: initial Phase 1 data on XmAb20717 in solid tumors
• MacroGenics Inc MGNX: Phase 1 data on MGD013 in solid tumors; Phase 1/2 data for MGC018 in solid tumors
• DelMar Pharmaceuticals Inc DMPI: Phase 2 data on VAL-083 in unmethylated newly diagnosed glioblastoma multiforme
• Salarius Pharmaceuticals Inc SLRX: Phase 1 data on seclidemstat in Ewing sarcoma
• AstraZeneca: Phase 3 data on Tagrisso in non-small cell lung carcinoma
• Genocea Biosciences Inc GNCA: updated Phase 1/2 data on GEN-009 vaccine for various cancers
• NextCure Inc NXTC: Phase 1 biomarker data on NC318 in solid tumors
• Spring Bank Pharmaceuticals Inc SBPH: Phase 1 data on SB 11285 in solid tumors
• Adaptimmune Therapeutics PLC – ADR ADAP: Summary of Phase 1 data on MAGE-A4 in solid tumors
• ZIOPHARM Oncology Inc. ZIOP: initial Phase 2 data on Ad-RTS-hIL-12, along with veledimex and Libtayo in refractory glioblastoma multiforme
• Agios Pharmaceuticals Inc AGIO: Phase 1 data on vorasidenib in IDHm low-grade glioma
• Oncternal Therapeutics Inc ONCT: updated Phase 1/2 data on cirmtuzumab and ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma
• Roche Holdings AG Basel ADR Common Stock RHHBY: Phase 2 data on tiragolumab and atezolizumab in non-small cell lung cancer
• Aptose Biosciences Inc APTO: Phase 1 data on CG-806 in chronic lymphocytic leukemia or non-Hodgkin lymphomas
• Kura Oncology Inc KURA: Phase 2 mature data on tipifarnib in head and neck squamous cell carcinomas with HRAS Mutations
• Innate Pharma SA IPHA: Phase 2 second cohort expansion data on monalizumab in combination with cetuximab in squamous cell carcinoma of the head and neck
• Imv Inc IMV:: updated Phase 1b data on DPX-Survivac and epacadostat in ovarian cancer
• MEI Pharma Inc MEIP: updated Phase 1b data on ME-401 in relapsed/refractory follicular lymphoma/chronic lymphocytic leukemia
• TapImmune Inc. common stock MRKR: updated Phase 1/2 data on MultiTAA-Specific T Cells in pancreatic cancer
• Inovio Pharmaceuticals Inc INO:: Phase 1/2 12-month overall survival data on INO-5401 in glioblastoma

ISCT Presentations

Mesoblast limited MESO: oral presentation of results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease

ASCP Presentations

Karuna Therapeutics Inc KRTX will present additional data from the Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.

Earnings

Wednesday

• REDHILL BIOPHAR/S ADR RDHL (before the market open)
• Trinity Biotech plc TRIB (before the market open)

Thursday

• Adverum Biotechnologies Inc ADVM (after the close)
• Geron Corporation GERN (after the close)

IPO Quiet Period Expiry

Lyra Therapeutics Inc LYRA

Correction: Clovis Oncology Inc's CLVS Phase 1b/2 data on the Opdivo-lucitanib combo is due at a medical meeting in fall of 2020.